Registry tracking frailty and aging in older adults with blood cancers
Records frailty and aging health in people aged 50 and older with blood cancers.
Plain-language title generated from the registry record
Registry title: Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Key facts
- Where
- Birmingham, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with a biopsy-proven blood cancer who have appointments at UAB. It builds a registry to learn about frailty and age-related problems.
- Age
- 50 years or older
- Sex
- All sexes can join. No exclusions based on gender, ethnicity or race.
- Disease stage
- A biopsy-proven blood cancer, such as multiple myeloma, AL amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin or Non-Hodgkin lymphoma, myelodysplastic syndromes, myeloproliferative neoplasm, or acute or chronic myeloid or lymphoid leukemia.
Main reasons for not taking part
- Under 50 years old
- Does not read or speak English
Read by machine on 9 November 2026.
Where in United States
- Kirklin Clinic of UAB HospitalBirmingham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT05556928
- Record updated
- 8 December 2025
- Original description
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.Read full original descriptionShow less
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.
Inclusion: Patients are ≥50 years of age; Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia); Patients have appointments at UAB including if they are an inpatient or other clinic locations.
Exclusion: Individuals who are <50 years old; Patients who do not read and/or speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race.